Avandia: Pros and Cons

http://www.medpagetoday.com

CHICAGO -- In the month since the New England Journal of Medicine published a meta-analysis that linked use of rosiglitazone (Avandia) to an increased risk of myocardial infarction, controversy surrounding the use of this popular diabetes drug has continued unabated. Earlier this month a Congressional hearing investigated the FDA's handling of rosiglitazone and several medical journals have weighed in with editorials on the controversy. The American Diabetes Association addressed the issue at a special symposium.

MedPage Today examines both sides of the controversy in this exclusive report from Multimedia Producer Greg Laub, with Crystal Phend, MedPage Today staff writer and Neil Osterweil, MedPage Today Senior Associate Editor.

Category:

Education

Tags:

• medicine
• health